Efficacy and Safety of Elobixibat in Parkinson's Disease with Chronic Constipation: CONST-PD Study.

ABSTRACT:

Background

Chronic constipation is a common digestive complication of Parkinson's disease (PD).

Objectives

To verify the usefulness of elobixibat, an ileal bile acid transporter inhibitor, for chronic constipation in PD.

Methods

This double-blind, placebo-controlled study consisted of a 2-week observation/washout period and a 4-week treatment period. All patients received a Bowel Movement Diary at Week -2 and were allocated to elobixibat (10 mg) or placebo at Week 0. Patients visited at Weeks 2 and 4 to report daily spontaneous bowel movements (SBM), stool form, drug use, quality of life (QOL), and safety. Changes in these parameters were assessed.

Results

The study included 38 patients in the elobixibat group and 39 in the placebo group, and 37 each completed

SUBMITTER: Hatano T 

PROVIDER: S-EPMC10982595 | biostudies-literature | 2024 Apr

REPOSITORIES: biostudies-literature